Furthermore, recent studies, including our own, have highlighted a significant link between lipid accumulation and the oncogenic factor HIF-2α, suggesting that targeting lipid metabolism pathways, including key enzymes like FASN, could provide new therapeutic opportunities for ccRCC [9–11]. Here, FASN is linked to nonpapillary renal cell carcinoma.